Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $281,097.18 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 10,218 shares of the stock in a transaction on Friday, October 4th. The stock was sold at an average price of $27.51, for a total value of $281,097.18. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Monday, October 7th, Benjamin Hohl sold 1,270 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.51, for a total transaction of $34,937.70.
• On Friday, September 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.27, for a total transaction of $103,147.50.
• On Monday, September 30th, Benjamin Hohl sold 2,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.33, for a total transaction of $50,660.00.
• On Tuesday, August 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.54, for a total transaction of $95,795.00.
• On Wednesday, July 31st, Benjamin Hohl sold 991 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.53, for a total value of $27,282.23.
• On Monday, July 29th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $26.68, for a total value of $140,070.00.
• On Friday, July 12th, Benjamin Hohl sold 3,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.07, for a total value of $75,210.00.

Enliven Therapeutics Price Performance

ELVN opened at $26.97 on Friday. The firm has a market capitalization of $1.27 billion, a P/E ratio of -13.97 and a beta of 1.10. Enliven Therapeutics, Inc. has a one year low of $9.80 and a one year high of $28.62. The company has a fifty day moving average price of $23.34 and a 200-day moving average price of $22.22.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Tuesday, August 13th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.17. On average, analysts expect that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $37.00 price target on shares of Enliven Therapeutics in a research report on Tuesday, October 1st.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ELVN. SG Americas Securities LLC bought a new stake in Enliven Therapeutics during the third quarter valued at approximately $256,000. The Manufacturers Life Insurance Company bought a new position in shares of Enliven Therapeutics in the 2nd quarter worth $322,000. Marshall Wace LLP purchased a new stake in shares of Enliven Therapeutics during the 2nd quarter valued at $4,489,000. First Turn Management LLC purchased a new stake in Enliven Therapeutics during the second quarter valued at about $9,657,000. Finally, Nicholas Investment Partners LP purchased a new position in shares of Enliven Therapeutics in the 2nd quarter worth about $1,310,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.